Insulin Mediated Lipohypertrophy
Published: 2023-07-01
Page: 87-91
Issue: 2023 - Volume 6 [Issue 1]
Manda Anusha *
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telanagana, India.
Jannapala Anusha
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telanagana, India.
Adiba Nousheen
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telanagana, India.
Enara Bawani
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telanagana, India.
Sangareddy Jayanth Kumar
Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telanagana, India.
*Author to whom correspondence should be addressed.
Abstract
Insulin is used to treat diabetes Type I and II. This article explains how a lipohypertrophy is caused by the insulin and explains the precautions that should be taken during the administration of insulin. Lipohypertrophy (LH) is a typical side effect of insulin therapy in subcutaneous tissue. Several injections at the same place result in this problem. A potential underlying mechanism of lipohypertrophy is the production of insulin antibodies. Recognizing and effectively managing these problems are crucial. In order to detect mild forms of lipohypertrophy, every patient should have their lips thoroughly evaluated for the condition during a diabetes clinic evaluation. The best current preventative and therapeutic approaches for lipohypertrophy are non-reuse of needles and rotation of injection sites with each injection. Education for both doctors and patients on recognising and treating lipohypertrophy is advisable.
Keywords: Diabetes, insulin, lipohypertrophy